Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
Date:8/1/2011

f Arena's most advanced drug candidate and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looki
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
2. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
3. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
7. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
9. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
10. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... July 31, 2014 Nektar Therapeutics (Nasdaq: ... quarter ended June 30, 2014. Cash and ... million as compared to $309.1 million at March 31, 2014."The ... Nektar as we look forward to significant milestones for a ... President and Chief Executive Officer of Nektar. "The first of ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
(Date:8/1/2014)... Cannabis use among young people has spiked, ... 17 having used marijuana at least once and 17 percent ... ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from the ... this summer with factual information about drugs, to help reverse ... “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers have ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... Gray HealthDay Reporter FRIDAY, Aug. ... in manufacturing jobs may have significantly less endurance than those who ... 32 people -- half were obese, half were of normal weight ... about 60 percent longer. Obesity also was associated with less ... Being older -- 50 to 65 years of age -- neither ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... WEDNESDAY, Oct. 26 (HealthDay News) -- A vaccine to prevent ... bisexual males, according to a study funded in part by ... papilloma virus (HPV), the most common sexually transmitted disease in ... and bisexual men and people infected with HIV. , ...
... the nipple is highly effective in animal models of early ... patients, according to a report by Johns Hopkins Kimmel Cancer ... 26. The results of the study are expected to lead ... early breast cancer. "Our results support the theory that ...
... human eye is as comfortable with white light generated ... popular light-emitting diodes (LEDs), according to tests conceived at ... through material to generate light, but the simpler LED ... light back and forth internally before releasing it. ...
... University Hospital surgeons found that a carefully-selected surgical care ... by nearly 50 percent. Smoking cessation at ... prior to skin closure, and using clippers over razors to ... helped reduced infection rates, according to the study published in ...
... what is so far the largest investigation of its kind, ... diseases and how they are affected by differences between two ... highly targeted, individualized therapies. Led by researchers from Weill ... edition of the journal Nature , the study provides ...
... Bisphenol A (BPA) -- a substance that may have ... thermal cash register receipts, scientists are reporting. The recycling ... BPA contamination of paper napkins, toilet paper, food packaging ... special implications for cashiers and other people who routinely ...
Cached Medicine News:Health News:HPV Vaccine Might Help Prevent Anal Cancers: Study 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 3Health News:High-quality white light produced by four-color laser source 2Health News:High-quality white light produced by four-color laser source 3Health News:Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures 2Health News:Study identifies genetic basis of human metabolic individuality 2
Precision has its new line of programmable autoclaves which are easy to use bench-top autoclaves or models to fit any need. It has 4 adjustable sterilization programs, touch button control panel, man...
HRT II is the smallest scanning laser ever, light, portable and ready for telemedicine....
... The Horizon Phacoemulsification System ... surgical system. Lightweight and portable, ... features in a small console. ... necessary to perform anterior segment ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: